LEADER 02263oam 2200589 450 001 9910705756403321 005 20171106114252.0 035 $a(CKB)5470000002452843 035 $a(OCoLC)990339814$z(OCoLC)993641294$z(OCoLC)999360943 035 $a(EXLCZ)995470000002452843 100 $a20170621d2017 ua 0 101 0 $aeng 135 $aurbn||||a|||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aChina's technological rise $echallenges to U.S. innovation and security : hearing before the Subcommittee on Asia and the Pacific of the Committee on Foreign Affairs, House of Representatives, One Hundred Fifteenth Congress, first session, April 26, 2017 210 1$aWashington :$cU.S. Government Publishing Office,$d2017. 215 $a1 online resource (iii, 96 pages) $cillustrations 300 $aPaper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office. 300 $a"Serial No. 115-22." 320 $aIncludes bibliographical references. 517 $aChina's technological rise 606 $aTechnological innovations$xEconomic aspects$zChina 606 $aHigh technology industries$zChina 606 $aAerospace industries$zChina 606 $aInternet in espionage$zChina 606 $aInternet in espionage$zUnited States 606 $aCyberspace$xSecurity measures$zUnited States 606 $aCyberinfrastructure$xSecurity measures$zUnited States 607 $aChina$xForeign economic relations$zUnited States 607 $aUnited States$xForeign economic relations$zChina 608 $aLegislative hearings.$2lcgft 615 0$aTechnological innovations$xEconomic aspects 615 0$aHigh technology industries 615 0$aAerospace industries 615 0$aInternet in espionage 615 0$aInternet in espionage 615 0$aCyberspace$xSecurity measures 615 0$aCyberinfrastructure$xSecurity measures 801 0$bGPO 801 1$bGPO 801 2$bGPO 801 2$bAZP 801 2$bMERUC 801 2$bIOG 801 2$bOCLCQ 801 2$bGPO 906 $aBOOK 912 $a9910705756403321 996 $aChina's technological rise$93462702 997 $aUNINA LEADER 03807nam 22006255 450 001 9910300183703321 005 20200701093547.0 010 $a3-319-07410-5 024 7 $a10.1007/978-3-319-07410-8 035 $a(CKB)3710000000269884 035 $a(EBL)1965119 035 $a(SSID)ssj0001372837 035 $a(PQKBManifestationID)11782344 035 $a(PQKBTitleCode)TC0001372837 035 $a(PQKBWorkID)11310810 035 $a(PQKB)11298279 035 $a(DE-He213)978-3-319-07410-8 035 $a(MiAaPQ)EBC1965119 035 $a(PPN)182092763 035 $a(EXLCZ)993710000000269884 100 $a20141031d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aWhite Coat Hypertension $eAn Unresolved Diagnostic and Therapeutic Problem /$fby Giuseppe Mancia, Guido Grassi, Gianfranco Parati, Alberto Zanchetti 205 $a1st ed. 2015. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015. 215 $a1 online resource (153 p.) 300 $aDescription based upon print version of record. 311 $a3-319-07409-1 320 $aIncludes bibliographical references. 327 $a1 Historical Notes -- 2 Definition, Terminology and Prevalence -- 3 Diagnostic Approach to white coat effect and white coat hypertension -- 4 Neurogenic and Non-neurogenic Mechanisms -- 5 Predictive Factors -- 6 White coat hypertension and cardiovascular morbidity and mortality -- 7 White coat hypertension and Target Organ Damage -- 8 White Coat Hypertension, metabolic risk factors, and cardiovascular risk profile -- 9 To Treat or Not To Treat?. 330 $aThis book addresses all aspects of white coat hypertension ? the phenomenon of raised blood pressure in a medical setting yet not elsewhere ? from its history to its pathophysiology, diagnosis and treatment. White coat hypertension is a common condition, accounting for 30?40% of the overall hypertensive population. While many studies have addressed this condition, controversy still exists over whether it causes an increased risk to sufferers and should be treated.  In the volume neurogenic and non-neurogenic mechanisms are discussed and the significance of various predictive factors, evaluated. The association of white coat hypertension with dysmetabolic risk factors, new-onset diabetes and other conditions is carefully reviewed. Further chapters consider the occurrence of asymptomatic organ damage and cardiovascular outcomes in affected patients, and helpful guidance is also provided on the controversial issue of when to treat and when not to treat. White Coat Hypertension is based largely on work done during the past 30 years by renowned researchers working in Milan, who have made key contributions in improving knowledge of the condition and whose work is well known across the world. 606 $aCardiology 606 $aDiabetes 606 $aCardiology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33037 606 $aDiabetes$3https://scigraph.springernature.com/ontologies/product-market-codes/H33045 615 0$aCardiology. 615 0$aDiabetes. 615 14$aCardiology. 615 24$aDiabetes. 676 $a610 676 $a616.12 676 $a616.46 676 $a616462 700 $aMancia$b Giuseppe$4aut$4http://id.loc.gov/vocabulary/relators/aut$01062846 702 $aGrassi$b Guido$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aParati$b Gianfranco$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aZanchetti$b Alberto$4aut$4http://id.loc.gov/vocabulary/relators/aut 906 $aBOOK 912 $a9910300183703321 996 $aWhite Coat Hypertension$92528726 997 $aUNINA